Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

• Authors: RICHTER J.; LUBKING A.; SODERLUND S.; LOTFI K.; MARKEVARN B.; SJALANDER A.; STENKE L.; DENEBERG S.; AHLSTRAND E.; MYHR-ERIKSSON K.; PANAYIOTIDIS P.; GEDDE-DAHL T.; ŽÁČKOVÁ Daniela; MAYER Jiří; OLSSON-STROMBERG U.; MAHON F. X.; SAUSSELE S.; HJORTH-HANSEN H.; KOSKENVESA P.
• Year of publication: 2021
• Type: Article in Periodical
• Magazine / Source: Leukemia
• MU Faculty or unit: Faculty of Medicine
• web: https://www.nature.com/articles/s41375-021-01173-w.pdf
• Doi: https://doi.org/10.1038/s41375-021-01173-w
• Keywords: TKI discontinuation; CML; MMR-final report; AFTER-SKI
• Description: Discontinuation of tyrosine kinase inhibitor (TKI) treatment for chronic phase (CP) CML patients with a deep molecular response (DMR) has entered standard practice. This is based on numerous clinical studies showing that ~50% of patients with DMR can stop TKI treatment without imminent disease relapse. However, in most of these trials long-term follow-up has been limited.